Characteristics

Anti-IFNg

Anti-TNFa

Placebo

No. of patients

20

20

15

Gender, M/F

2/18

5/15

2/13

Age, years

49.30 ± 11.45

50.85 ± 11.39

56.93 ± 9.30

Disease duration, years

9.62 ± 7.49

14.3 ± 8.77

8.13 ± 8.76

Rheumatoid factor +

17

15

13

Pain, VAS, cm

6.15 ± 1.64

6.22 ± 1.47

6.89 ± 1.54

Morning stiffness, min.

129.25 ± 111.05

101.00 ± 105.11

115.33 ± 107.42

Health physician

status (1 - 5) patient

3.55 ± 0.51

3.45 ± 0.51

3.46 ± 0.51

3.70 ± 0.57

3.5 ± 0.51

3.80 ± 0.67

No. of swollen joints

10.60 ± 5.49

10.0 ± 5.31

9.06 ± 2.98

No. of tender joints

21.30 ± 8.35

20.20 ± 7.97

22.73 ± 5.52

Grip strength, right

KPa left

31.55 ± 20.71

37.70 ± 22.87

26.13 ± 11.519

27.45 ± 16.70

33.90 ± 29.53

19.06 ± 6.46

Fatigue, VAS, cm

6.35 ± 1.81

6.87 ± 1.83

6.97 ± 2.1

Hemoglobin, g/L

113.44 ± 18.27

117.36 ± 18.92

113.5 ± 16.51

ESR, mm/hour

35.83 ± 10.55

34.15 ± 10.92

43.00 ± 12.94

CRP, mg/dL

2.3 ± 1.35

2.37 ± 2.54

2.5 ± 3.39

Patients on stable dose of prednisolone

5

6

4

Number of previous

DMARDs

1.9

2.1

1.8